Lund, Sweden – September 20, 2023 – Fåhraeus Startup & Growth Fund II (FSG) today announces its investment in OssDsign, a Swedish medtech company developing next-generation orthobiologics for bone healing. The investment was made through a directed share issue on Nasdaq First North Growth Market, where OssDsign is listed.

OssDsign develops and markets bone replacement products based on cutting-edge material science, supporting the body’s own healing across a range of orthopaedic areas with high medical needs. Its portfolio includes patient-specific cranial implants and the off-the-shelf synthetic bone graft Catalyst, which has seen strong growth in the US spine market.

“OssDsign is a well-run company with a product portfolio that is gaining real traction, particularly with Catalyst in the United States. We see significant potential in next-generation orthobiologics and are pleased to back the company in this phase of growth,” said Christer Fåhraeus, General Partner at FSG.

“We welcome FSG as an investor. Their long-term perspective and life-science expertise align well with our ambition to make Catalyst a new standard of care in bone healing,” said Morten Henneveld, CEO of OssDsign.

About OssDsign

OssDsign is a Swedish medtech company developing next-generation orthobiologics. Its products, including the synthetic bone graft Catalyst, support the body’s own healing to improve clinical outcomes in spine and cranial surgery. OssDsign is listed on Nasdaq First North Growth Market in Stockholm.

About Fåhraeus Startup & Growth (FSG)

Fåhraeus Startup & Growth FSG Fund II (FSG) is a leading Nordic venture capital fund specializing in supporting high-impact startups and growth-stage companies in technology and life sciences. FSG combines strategic investments with deep industry expertise to empower transformative innovations. FSG Fund II is supported by the European Investment Fund (EIF).